



Acquisition of own shares in the framework of employees' long-term incentive plans

BRUSSELS, Belgium, 28 April 2011 – 19:30 (CET) – regulated information - In application of art. 207 of the Royal Decree executing the Company Code, UCB publishes having acquired 41,770 UCB shares on the Brussels stock exchange on the dates and at the prices indicated hereunder:

Date	Amount	Price EUR
21/4/2011	3,500	31.6000
21/4/2011	500	30.7700
26/4/2011	7,690	32.1000
26/4/2011	8,580	31.0500
26/4/2011	6,700	32.3000
27/4/2011	2,800	32.0000
27/4/2011	9,500	32.4700
27/4/2011	2,500	32.2750

These shares were immediately distributed to the employees who have exercised share options that had been granted to them in the framework of existing Company's share option plans of which the detail is given in UCB annual report.

UCB S.A. - Allée de la Recherche, 60 - 1070 Bruxelles - RPM 0403.053.608

For further information

Antje Witte, Investor Relations, UCB
T +32.2.559.9414, antje.witte@ucb.com

Nancy Nackaerts, External Communications, UCB
T +32 473 86 44 14, nancy.nackaerts@ucb.com

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8 500 people in about 40 countries, the company generated revenue of EUR 3.2 billion in 2010. UCB is listed on Euronext Brussels (symbol: UCB).

Forward-looking statements

This press release contains forward-looking statements based on current plans, estimates and beliefs of management. Such statements are subject to risks and uncertainties that may cause actual results to be materially different from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, effects of future judicial decisions, changes in regulation, exchange rate fluctuations and hiring and retention of its employees.